New Two-Pronged drug tested for rare chest cancers
NCT ID NCT04417660
Summary
This study is testing an experimental drug called bintrafusp alfa for people with advanced thymoma or thymic carcinoma that has returned or worsened after standard chemotherapy. The drug is designed to work in two ways to help the immune system fight the cancer. Participants receive the drug through an IV every two weeks to see if it can shrink tumors and control the disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THYMIC EPITHELIAL TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
Conditions
Explore the condition pages connected to this study.